Segmented Gap HBV Oligonucleotides for Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HBV antisense oligonucleotides with continuous gap segments exhibit minimal efficacy in reducing serum HBsAg and HBsAg levels and pose safety concerns, necessitating improved therapeutic options for chronic hepatitis B.
Innovation Solution
Development of HBV antisense oligonucleotides with segmented gap structures incorporating specific nucleoside modifications and separator segments at strategic positions to enhance activity and reduce in vivo toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If continuous gap segment oligonucleotides are used, then oligonucleotide structure is simple, but therapeutic efficacy is minimal and safety concerns arise
Solution Approach 1:
The patent applies segmentation by dividing the continuous gap segment into multiple sub-segments separated by separator segments. This creates a segmented gap structure where the gap is no longer continuous but divided into discrete portions, which improves therapeutic efficacy while managing structural complexity through systematic design
Solution Approach 2:
The patent implements local quality by introducing specific modifications at particular positions within the oligonucleotide structure. Different regions (5' wing, gap segments, separator segments, 3' wing) have distinct nucleoside compositions and modifications tailored to optimize specific functions such as binding affinity, stability, and reduced toxicity
2Reliability
If nucleoside modifications are increased to enhance activity, then therapeutic efficacy improves, but in vivo toxicity increases
Solution Approach 1:
The patent applies local quality by strategically placing specific nucleoside modifications only in certain regions of the oligonucleotide while leaving other regions unmodified or differently modified. This localized approach maximizes therapeutic efficacy at the target site while minimizing off-target effects and in vivo toxicity
Solution Approach 2:
The segmented structure allows different regions to have different modification profiles. The separator segments and gap segments can have distinct modification patterns that optimize activity locally without uniformly increasing toxicity throughout the entire molecule
3Ease of manufacture
If oligonucleotide structure is simplified, then manufacturing is easier, but activity reduction capability is minimal
Solution Approach 1:
The segmented gap structure is designed with repeating units and standardized separator segments that can be synthesized using modular approaches, maintaining relative ease of manufacture while achieving superior activity reduction capability through the segmented architecture
Solution Approach 2:
The patent employs universal building blocks and standardized separator segments that can be used across different oligonucleotide designs, maintaining manufacturing efficiency while the segmented structure provides enhanced multi-functional capabilities for activity reduction
Data Source
AI summary
Disclosed herein are modified oligonucleotides complementary to a portion of a Hepatitis B virus (HBV) genome, wherein the modified oligonucleotides comprise a 5′ wing segment, a first gap segment, a first separator segment comprising a 2′ sugar modification, a second gap segment, and a 3′ wing segment. Such modified oligonucleotides are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.